Acute Kidney Injury Market

Market Overview:

The 7 major acute kidney injury markets reached a value of US$ 5,766.5 Million in 2024. Looking forward, IMARC Group expects the 7MM to reach US$ 9,904.0 Million by 2034, exhibiting a growth rate (CAGR) of 5.04% during 2024-2034.

The acute kidney injury market has been comprehensively analyzed in IMARC’s new report titled “Acute Kidney Injury Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034”. Acute kidney injury (AKI) is a sudden and often reversible decline in kidney function that typically occurs over a short period of time, usually within hours to days. It is characterized by an increase in levels of waste products in the blood, fluid overload, and electrolyte imbalances. Acute kidney injury can be caused due to several factors, such as reduced blood flow to the kidneys, severe infections, blockage of the urinary tract, prolonged use of certain medications, etc. Some common symptoms of the ailment include swelling in the legs, ankles, or feet, decreased urine output, shortness of breath, chest pain, seizures, muscle twitching, etc. Acute kidney injury is diagnosed using a combination of physical examination and lab tests. Generally, blood tests are utilized to assess creatinine and blood urea nitrogen (BUN) levels. Additionally, urine tests may be carried out to measure the amount of protein and red and white blood cells in the urine, which can indicate kidney damage. Various imaging tests, such as ultrasound, CT scan, and MRI, can also be used to visualize the kidneys and urinary tract.

The rising prevalence of certain medical conditions, such as sepsis and lupus nephritis, along with the increasing cases of direct kidney injury from drugs or toxins are primarily driving the global acute kidney injury market. In addition to this, the escalating utilization of several medications,  including angiotensin-converting enzyme inhibitors (ACE inhibitors) and angiotensin receptor blockers (ARBs), to manage blood pressure and reduce the risk of further kidney damage is also bolstering the market growth. Besides this, the growing awareness regarding the importance of early detection and diagnosis of AKI, as prompt intervention can lower the chances of severe complications and improve patient outcomes, is further propelling the global market. Additionally, several key players are making extensive investments in realizing the potential of regenerative medicine and stem cell therapy for treating AKI since they show promise in restoring normal kidney function and reducing the need for dialysis. This, in turn, is also bolstering the market growth. Apart from this, the ongoing advancements in the field of nephrology, which are further augmenting the development of new drugs, devices, and diagnostic tools for AKI, are expected to drive the global acute kidney injury market in the coming years.

IMARC Group’s new report provides an exhaustive analysis of the acute kidney injury market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for acute kidney injury and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the acute kidney injury market in any manner.

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the acute kidney injury market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the acute kidney injury market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current acute kidney injury marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the acute kidney injury market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2034?
• What was the country-wise size of the acute kidney injury market across the seven major markets in 2024 and what will it look like in 2034?
• What is the growth rate of the acute kidney injury market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (​2018-2034​) of acute kidney injury across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of acute kidney injury by age across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of acute kidney injury by gender across the seven major markets?
• How many patients are diagnosed (​2018-2034​) with acute kidney injury across the seven major markets?
• What is the size of the acute kidney injury patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of acute kidney injury?
• What will be the growth rate of patients across the seven major markets?
   

Acute Kidney Injury: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for acute kidney injury drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the acute kidney injury market?
• What are the key regulatory events related to the acute kidney injury market?
• What is the structure of clinical trial landscape by status related to the acute kidney injury market?
• What is the structure of clinical trial landscape by phase related to the acute kidney injury market?
• What is the structure of clinical trial landscape by route of administration related to the acute kidney injury market?